Chung Hyo Kyun, Lee In Kyu, Kang Hyokyung, Suh Jae Mi, Kim Ho, Park Ki Cheol, Kim Dong Wook, Kim Young Kun, Ro Heung Kyu, Shong Minho
Department of Internal Medicine, School of Medicine, Chungnam National University, Daejon 301-721, Korea.
Exp Mol Med. 2002 Dec 31;34(6):451-61. doi: 10.1038/emm.2002.63.
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, are widely used for primary and secondary prevention of coronary artery atherosclerosis. Pathogenesis of atherosclerosis is multistep processes where transendothelial migration of various leukocytes including monocytes is a crucial step. Interferon-gamma (IFN-gamma) contributes in this process by activating macrophages and T-lymphocytes, and by inducing adhesion molecules in vascular endothelial and smooth muscle cells. In this study we investigated the expression of intercellular cell adhesion molecule-1 (ICAM-1) in transformed endothelial cell line ECV304 cells as influenced by lovastatin, tumor necrosis factor-alpha (TNF-alpha) and IFN-gamma. Results show that lovastatin suppresses expression of ICAM-1 by inhibiting the IFN-gamma-induced extracellular signal-regulated kinase (ERK) p44/p42-STAT1 signaling pathway. In cells treated with lovastatin and IFN-gamma, ICAM-1 was expressed at a lower level than in cells treated with IFN-gamma alone. However, lovastatin does not reduce TNF-alpha induced expression of ICAM-1. A similar result was observed in cells treated with the MEKK inhibitor PD98059 and IFN-gamma. Cis-acting DNA sequence elements were identified in the 5'-flanking region of the ICAM-1 promoter that mediate inhibition by lovastatin; these sequences map to the IFN-gamma activated site which also binds the STAT1 homodimer. However, lovastatin did not inhibit IFN-gamma-mediated induction of the Y701 phosphorylated form of STAT1. But lovastatin does inhibit the IFN-gamma-mediated phosphorylation of ERK1/ERK2 (T202/Y204) and S727 phosphorylation of STAT1. TNF-alpha does not induce phosphorylation of ERK1/ERK2 and S727 in ECV304 and smooth muscle cells. The results provide the evidences that statins may have beneficial effects by inhibiting IFN-gamma action in atherosclerotic process
3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,即他汀类药物,被广泛用于冠状动脉粥样硬化的一级和二级预防。动脉粥样硬化的发病机制是多步骤过程,其中包括单核细胞在内的各种白细胞的跨内皮迁移是关键步骤。干扰素-γ(IFN-γ)通过激活巨噬细胞和T淋巴细胞,并诱导血管内皮和平滑肌细胞中的黏附分子,在这一过程中发挥作用。在本研究中,我们调查了洛伐他汀、肿瘤坏死因子-α(TNF-α)和IFN-γ对转化内皮细胞系ECV304细胞中细胞间黏附分子-1(ICAM-1)表达的影响。结果表明,洛伐他汀通过抑制IFN-γ诱导的细胞外信号调节激酶(ERK)p44/p42-STAT1信号通路来抑制ICAM-1的表达。在用洛伐他汀和IFN-γ处理的细胞中,ICAM-1的表达水平低于仅用IFN-γ处理的细胞。然而,洛伐他汀不会降低TNF-α诱导的ICAM-1表达。在用MEKK抑制剂PD98059和IFN-γ处理的细胞中也观察到了类似结果。在ICAM-1启动子的5'侧翼区域鉴定出顺式作用DNA序列元件,其介导洛伐他汀的抑制作用;这些序列定位于IFN-γ激活位点,该位点也结合STAT1同二聚体。然而,洛伐他汀并未抑制IFN-γ介导的STAT1 Y701磷酸化形式的诱导。但洛伐他汀确实抑制IFN-γ介导的ERK1/ERK2(T202/Y204)磷酸化和STAT1的S727磷酸化。TNF-α不会诱导ECV304和平滑肌细胞中ERK1/ERK2和S727的磷酸化。这些结果提供了证据,表明他汀类药物可能通过抑制IFN-γ在动脉粥样硬化过程中的作用而具有有益效果